Robeco Institutional Asset Management B.V. cut its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 14.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 148,237 shares of the company's stock after selling 24,091 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.18% of IDEXX Laboratories worth $62,252,000 at the end of the most recent reporting period.
Other hedge funds also recently made changes to their positions in the company. Hurley Capital LLC purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $29,000. Rialto Wealth Management LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at $30,000. Colonial Trust Co SC lifted its stake in shares of IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after buying an additional 39 shares in the last quarter. Itau Unibanco Holding S.A. lifted its stake in shares of IDEXX Laboratories by 540.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after buying an additional 81 shares in the last quarter. Finally, Retirement Wealth Solutions LLC boosted its holdings in IDEXX Laboratories by 40.0% in the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock worth $44,000 after buying an additional 30 shares during the period. 87.84% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on IDXX. Wall Street Zen downgraded IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. Leerink Partners boosted their price target on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a report on Wednesday, June 11th. Stifel Nicolaus upped their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Finally, Morgan Stanley upped their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $546.00.
Check Out Our Latest Stock Report on IDEXX Laboratories
Insider Transactions at IDEXX Laboratories
In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction dated Wednesday, May 21st. The shares were sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the transaction, the director now owns 1,801 shares of the company's stock, valued at approximately $922,724.34. This trade represents a 41.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.98% of the company's stock.
IDEXX Laboratories Price Performance
NASDAQ IDXX traded up $3.54 during trading on Friday, hitting $531.32. 624,759 shares of the stock traded hands, compared to its average volume of 645,456. The company has a quick ratio of 0.81, a current ratio of 1.16 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $538.89. The firm has a 50-day simple moving average of $496.62 and a 200-day simple moving average of $450.16. The company has a market capitalization of $42.73 billion, a P/E ratio of 49.11, a price-to-earnings-growth ratio of 3.87 and a beta of 1.55.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same period in the prior year, the company earned $2.71 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. As a group, analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Further Reading
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
